JPJesse E. Passman

Jesse E. Passman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jesse E. Passman has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of a novel risk stratification model for primary aldosteronism

    by Julia A. Gasior, Sara P. Ginzberg, Daniel Herman, Saiesh Kalva, Christopher J. Wirtalla, Jesse E. Passman, Debbie L. Cohen, Jordana B. Cohen, Heather Wachtel

  • Impact of Serious Mental Illness and Dementia‐Related Disorders on Post‐Parathyroidectomy Healthcare Utilization and Cost

    by Jasmine Hwang, Shane Williams, James Sharpe, Jesse E. Passman, Rachael Acker, Danielle Brown, Douglas L. Fraker, Heather Wachtel, Rachel R. Kelz

    Background and Objectives: Serious mental illness and dementia‐related disorders are associated with worse postoperative outcomes. We evaluated the impact of pre‐existing neuropsychiatric disorders on post‐parathyroidectomy healthcare utilization. Methods: Adult patients who underwent parathyroidectomy for primary hyperparathyroidism were identified in the Healthcare Cost and Utilization Project State Inpatient and Ambulatory Surgery Databases (2016–2021). Neuropsychiatric disorders were classified. The primary outcome was 30‐day readmission. Secondary outcomes were length of stay and costs (2021USD). Balancing weights were used for covariate adjustment. Subgroup analyses were performed in serious mental illness and dementia‐related disorder groups. Results: Of 10,733 parathyroidectomy patients, 1,249 (11.6%) had neuropsychiatric disorders: 60.5% mood, 58.8% anxiety, 5.1% dementia‐related, and 1.8% schizophrenia‐type disorders. Patients with neuropsychiatric disorders were younger and more likely to undergo emergent/urgent parathyroidectomy ( p < 0.001). There was no difference in adjusted odds of readmission between patients with and without neuropsychiatric disorders (0.91[95%CI 0.55, 1.49], p = 0.710). Adjusted length of stay was 0.20 days longer among patients with neuropsychiatric disorders ([95%CI: + 0.11, + 0.30]; p < 0.001). Adjusted encounter costs were similar between groups (median[IQI]: neuropsychiatric disorder $6767[5290,8589] vs. no neuropsychiatric disorder $6511[5259, 8550]; p = 0.080). Subgroup analyses showed similar results. Conclusions: Patients with neuropsychiatric disorders have similar parathyroidectomy readmission and cost. They have slightly longer length of stay that may ameliorate the risk of readmission.

  • Non-interruptive decision support to increase appropriate screening for primary hyperparathyroidism

    by Jesse E. Passman, Jasmine Hwang, Mika Epps, Justin Tang, Charles Chambers, MaryAnne Peifer, Jeremy J. Flood, Heather Wachtel, Tessa Cook, Rachel R. Kelz, et al.


  • Open Access

    Fewer Pills, Lower Bills: Antihypertensive and Cost Outcomes of Adrenalectomy in Primary Aldosteronism

    by Jesse E. Passman, Lily Owei, Colleen Brensinger, Taryn Barrett, Lauren R. Kelz, Jasmine Hwang, Jordana B. Cohen, Heather Wachtel

    Background: Primary aldosteronism (PA) can be treated surgically or medically depending on disease lateralization and surgical candidacy. There is a dearth of data directly comparing antihypertensive medication trajectories and costs between these strategies. Patients and Methods: We performed a retrospective cohort study of patients with new PA diagnoses and adrenal vein sampling to assess antihypertensive medication outcomes and treatment costs using Optum’s de-identified Clinformatics ® Data Mart Database (2004–2022). Patients were stratified by receipt of adrenalectomy versus medical management alone. The index time point was defined as adrenal vein sampling (AVS) for medically managed and adrenalectomy for surgically managed patients. Outcomes were assessed using regression models. Results: Of 911 patients, 52% underwent adrenalectomy and 48% medical therapy. Adrenalectomy patients were younger, with higher Elixhauser scores. Antihypertensive medication use (2.9 versus 2.8, p = 0.636) and costs did not differ at index. After 1 year, adrenalectomy patients used fewer antihypertensive medications (1.5 ± 1.4) than medically managed patients (2.5±1.5, p < 0.001). On regression, age ( β = 0.02, p = 0.002), male sex ( β = 0.40, p < 0.001), and baseline antihypertensive medications ( β = 0.43, p < 0.001) were associated with higher antihypertensive medication requirement. Adrenalectomy patients were prescribed 1.11 fewer antihypertensive medications at one year ( p < 0.001). In the resistant hypertension subcohort, adrenalectomy reduced antihypertensive medications by 1.35 ( p < 0.001). Adrenalectomy was associated with US $908 lower antihypertensive medication prescription costs ( p < 0.001) and 87% lower odds of potassium supplementation ( p < 0.001). Conclusions: Patients with PA who undergo adrenalectomy demonstrate a significant reduction in antihypertensive medications compared with medically managed patients. While there is significant upfront cost to surgical intervention, reduced long-term prescription costs are realized.


  • Open Access

    The Effect of Bariatric Surgery on Hypertension Outcomes: A Retrospective Cohort Study

    by Jesse E. Passman, Amanda Bader, Nadim Mahmud, Kristoffel R. Dumon, Heather Wachtel, Feibi Zheng, Jordana B. Cohen

    Metabolic and bariatric surgery (MBS) is an effective treatment for obesity and metabolic syndrome. Evidence regarding the impact of MBS on hypertension outcomes is limited by short-term follow-up. Thus, this retrospective cohort study was designed to compare blood pressure (BP) control, number of antihypertensive medications (AHMs), development of apparent treatment resistant hypertension (ATRH), and remission of hypertension between patients treated with and without MBS. Adults with BMI ≥ 35 kg/m2 and a new diagnosis of hypertension receiving care within the Veterans Health Administration system from 2000–2019 were included. Generalized estimating equations and time-updated Cox models with inverse probability of treatment weighting to address time-updated confounding were used. Over a median follow-up of 5.1 years, 183702 patients with BMI ≥ 35 kg/m2 and hypertension were managed medically and 3965 were managed surgically. At baseline, those who underwent MBS were more likely to be women than men (22 vs. 10%). Patients treated surgically demonstrated significantly better BP control over time, with an average 5.4 mm Hg (95% CI 4.9–5.9) lower systolic BP and 1.8 mm Hg (95% CI 1.5–2.1) lower diastolic BP. Compared to patients treated medically, those who received MBS had 32% higher likelihood of complete AHM discontinuation (95% CI 1.23–1.42). Patients treated with MBS were 14% less likely to develop ATRH (95% CI 0.78–0.95). Overall, among patients with obesity and hypertension, treatment with MBS was associated with durably improved BP control compared to medical management, including lower systolic and diastolic BPs, higher AHM cessation, and lower rates of ATRH.


  • Open Access

    Adrenal Pseudocyst Masquerading as Adrenocortical Carcinoma

    by Andrew C. Hu, Jesse E. Passman, Heather Wachtel

    Incidental adrenal cysts are quite rare and thus can present a diagnostic conundrum for even experienced clinicians. Here, we present the case of a patient with an incidentally identified 5 cm adrenal mass. Her evaluation was notable for evidence of mild autonomous cortisol secretion and imaging findings concerning for malignancy with possible invasion of the inferior vena cava. Adrenalectomy was performed; pathology ultimately demonstrated an adrenal cortical pseudocyst without evidence of malignancy. All patients with solid, high-density, or large adrenal tumors require further imaging for characterization and biochemical testing for hormone secretion. While simple, low-density adrenal adenomas and cysts do not require further imaging evaluation beyond non-contrast CT, mixed cystic and solid lesions or pseudocystic lesions should be evaluated similarly to solid tumors, with the caveat that pseudocysts cannot always be well-differentiated from benign cysts on imaging. All adrenal incidentalomas should be evaluated with a biochemical work-up to assess hormonal activity. Tumors suspicious for malignancy require surgical excision. Patients with benign, hormonally active tumors should be managed surgically or medically, according to their primary pathology.


  • Active Choice Nudge to Increase Screening for Primary Aldosteronism in At-Risk Patients

    by Jesse E Passman, Jasmine Hwang, Justin Bs Tang, Madeline Ba Fagen, Mika Msn Epps, MaryAnne MD Peifer, John T Howell, Jordana B Md Cohen, M Kit Delgado, Heather Md Wachtel, et al.

    BACKGROUND: Primary aldosteronism (PA) is the most common cause of secondary hypertension, yet screening remains startlingly infrequent. We describe (1) PA screening practices in a large, diverse health system, (2) the development of a computable phenotype for PA screening, and (3) the design and pilot deployment of an electronic health record (EHR)-based active choice nudge to recommend PA screening. STUDY DESIGN: A multidisciplinary team developed a multipronged intervention to improve PA screening informed by guidelines, expertise, and multivariable analyses of factors associated with screening. The intervention included EHR-based tools to automatically identify screen-eligible patients, an active choice nudge recommending screening for these patients, and screening result interpretation. The intervention was piloted across 2 primary care practices for 7 months. Screening frequencies were compared with clinics not receiving the intervention. RESULTS: The baseline frequency of screening of eligible patients within 1 year was 1.4%. Higher mean systolic blood pressure (odds ratio [OR] 1.4; p < 0.001), more antihypertensive medications (OR 1.3; p = 0.002), lower minimum serum potassium (OR 2.0; p = 0.001), specialist care (OR 3.0; p < 0.001), and Black race (OR 1.5; p = 0.001) were associated with a higher likelihood of screening. The refined computable phenotype identified a subcohort with a higher frequency of positive screening (8.6% vs 4.1%; p = 0.03). In a pilot study of an active choice nudge, a greater proportion of eligible patients were screened in the intervention clinics (16.4%) than in the nonintervention clinics (1.8%; p < 0.001). CONCLUSIONS: PA screening rates are low. This pilot study suggests an EHR-based nudge leveraging a precise computable phenotype can dramatically increase appropriate PA screening.


  • Open Access

    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies

    by Jesse E. Passman, Michael J. Kallan, Jeffrey L. Roberson, Sara P. Ginzberg, Wajid Amjad, Jacqueline M. Soegaard Ballester, Gabriella Tortorello, Douglas Fraker, Giorgos C. Karakousis, Edmund K. Bartlett, et al.

    Background: Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.Methods: The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients.Results: Colorectal cancer was the most frequent indication for metastasectomy (n = 57,644 cases), followed by lung cancer (n = 55,090 cases), breast cancer (n = 12,616 cases), renal cancer (n = 8427 cases), and melanoma (n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, +10.6%; p = .013) and melanoma (AAPC, +8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = .26), colorectal cancer (AAPC, +0.3%; p = .83), or renal cancer (AAPC, +2.3%; p = .36).Conclusions: Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.


  • Gastrointestinal surgery, malabsorptive conditions, and postoperative hypocalcemia after neck surgery

    by Jesse E. Passman, Sara Ginzberg, Julia A. Gasior, Lauren Krumeich, Colleen Brensinger, Amanda Bader, Jasmine Hwang, Rachel Kelz, Heather Wachtel